Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

BACKGROUND: STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year interim analysis was to determine the effectiveness of nata...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Neurol
Main Authors: Perumal, Jai, Fox, Robert J., Balabanov, Roumen, Balcer, Laura J., Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555913/
https://ncbi.nlm.nih.gov/pubmed/31176355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-019-1337-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados